Australia markets closed

    +107.50 (+1.44%)

    -0.0030 (-0.40%)
  • ASX 200

    +106.90 (+1.48%)
  • OIL

    +0.06 (+0.08%)
  • GOLD

    -2.40 (-0.13%)

    -615.15 (-1.39%)
  • CMC Crypto 200

    -65.92 (-7.75%)

Global Ascites Market Insights, Epidemiology and Market Forecasts 2021-2030 -

·4-min read

The "Ascites-Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to's offering.

The Ascites market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Ascites market size from 2021 to 2030. The report also covers current Ascites treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Scope of the Report

  • The report provides a descriptive overview of Ascites, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.

  • Comprehensive insight has been provided into the Ascites epidemiology and treatment.

  • Additionally, an all-inclusive account of both the current and emerging therapies for Ascites is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

  • A detailed review of the Ascites market; historical and forecasted is included in the report, covering the 7MM drug outreach.

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Ascites market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the Ascites market.

  • The companies and academics are working to assess challenges and seek opportunities that could influence Ascites R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • Major players are involved in developing therapies for Ascites. The launch of emerging therapies will significantly impact the Ascites market.

  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions Answered

Market Insights:

  • What was the Ascites market share (%) distribution in 2018 and how it would look like in 2030?

  • What would be the Ascites total market size as well as market size by therapies across the 7MM during the forecast period (2021-2030)?

  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Ascites market size during the forecast period (2021-2030)?

  • At what CAGR, the Ascites market is expected to grow at the 7MM level during the forecast period (2021-2030)?

  • What would be the Ascites market outlook across the 7MM during the forecast period (2021-2030)?

  • What would be the Ascites market growth till 2030 and what will be the resultant market size in the year 2030?

  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Ascites?

  • What is the historical Ascites patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?

  • What would be the forecasted patient pool of Ascites at the 7MM level?

  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Ascites?

  • Out of the above-mentioned countries, which country would have the highest population of Ascites during the forecast period (2021-2030)?

  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Ascites along with the approved therapy?

  • What are the current treatment guidelines for the treatment of Ascites in the US and Europe?

  • What are the Ascites marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?

  • How many companies are developing therapies for the treatment of Ascites?

  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Ascites?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ascites therapies?

  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Ascites and their status?

  • What are the key designations that have been granted for the emerging therapies for Ascites?

  • What are the 7MM historical and forecasted market of Ascites?

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting